Search Results - "Vangipuram, Kiran"

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy by Hertz, Daniel L, Kidwell, Kelley M, Vangipuram, Kiran, Li, Feng, Pai, Manjunath P, Burness, Monika, Griggs, Jennifer J, Schott, Anne F, Van Poznak, Catherine, Hayes, Daniel F, Lavoie Smith, Ellen M, Henry, N Lynn

“…Paclitaxel exposure, specifically the maximum concentration ( ) and amount of time the concentration remains above 0.05 μmol/L ( ), has been associated with…”
Get full text

Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study by Salgado, Teresa M., Quinn, Caroline S., Krumbach, Emily K., Wenceslao, Iris, Gonzalez, Martha, Reed, Holly L., Syverson, Jillian G., Etz, Rebecca S., Vangipuram, Kiran, Barker, Melissa R., Henry, N. Lynn, Farris, Karen B., Hertz, Daniel L.

“…Purpose Cases of chemotherapy-induced peripheral neuropathy (CIPN) under-reporting have been sporadically described in the literature, but no studies have…”
Get full text

Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy by Sun, Yihan, Kim, Jae Hyun, Vangipuram, Kiran, Hayes, Daniel F., Smith, Ellen M. L., Yeomans, Larisa, Henry, N. Lynn, Stringer, Kathleen A., Hertz, Daniel L.

“…Purpose Approximately 25% of breast cancer patients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN)…”
Get full text

Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy by Jennaro, Theodore S., Fang, Fang, Kidwell, Kelley M., Smith, Ellen M. Lavoie, Vangipuram, Kiran, Burness, Monika L., Griggs, Jennifer J., Van Poznak, Catherine, Hayes, Daniel F., Henry, N. Lynn, Hertz, Daniel L.

“…Purpose Approximately 25% of patients receiving weekly paclitaxel for breast cancer require treatment disruptions to avoid severe, irreversible peripheral…”
Get full text

Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study by Salgado, Teresa M., Liu, Jin, Reed, Holly L., Quinn, Caroline S., Syverson, Jillian G., Le-Rademacher, Jennifer, Lopez, Camden L., Beutler, Andreas S., Loprinzi, Charles L., Vangipuram, Kiran, Smith, Ellen M. Lavoie, Henry, N Lynn, Farris, Karen B., Hertz, Daniel L.

“…Discrepancies between clinicians’ assessment of chemotherapy-induced peripheral neuropathy (CIPN) and patient-reported outcomes (PRO) have been described,…”
Get full text

Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy by Marcath, Lauren A., Kidwell, Kelley M., Vangipuram, Kiran, Gersch, Christina L., Rae, James M., Burness, Monika L., Griggs, Jennifer J., Van Poznak, Catherine, Hayes, Daniel F., Smith, Ellen M. Lavoie, Henry, N. Lynn, Beutler, Andreas S., Hertz, Daniel L.

“…Aims Chemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5,…”
Get full text

EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity by Marcath, Lauren A, Kidwell, Kelley M., Smith, Ellen M. Lavoie, Vangipuram, Kiran, Gersch, Christina L, Burness, Monika Leigh, Griggs, Jennifer J., Van Poznak, Catherine H., Hayes, Daniel F., Henry, Norah Lynn, Beutler, Andreas S., Hertz, Daniel Louis

“…Abstract only 532 Background: Chemotherapy induced peripheral neuropathy (CIPN) is a common, debilitating paclitaxel side effect that has been primarily…”
Get full text

Vitamin D insufficiency and risk of paclitaxel-induced peripheral neuropathy by Jennaro, Theodore Salvatore, Smith, Ellen M. Lavoie, Vangipuram, Kiran, Kidwell, Kelley M., Burness, Monika Leigh, Griggs, Jennifer J., Van Poznak, Catherine H., Hayes, Daniel F., Henry, Norah Lynn, Hertz, Daniel Louis

“…Abstract only e12027 Background: Peripheral neuropathy (PN) is a severe, dose-limiting toxicity of paclitaxel that occurs in up to 25% of patients and can lead…”
Get full text

Genetic variation in Charcot–Marie–Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy by Chen, Yongzhen, Fang, Fang, Kidwell, Kelley M, Vangipuram, Kiran, Marcath, Lauren A, Gersch, Christina L, Rae, James M, Hayes, Daniel F, Lavoie Smith, Ellen M, Henry, N Lynn, Beutler, Andreas S, Hertz, Daniel L

“…This study explored whether inherited variants in genes causing the hereditary neuropathy condition Charcot–Marie–Tooth disease are associated with sensitivity…”
Get full text

Patients carrying CYP2C83 have shorter systemic paclitaxel exposure by Marcath, Lauren A, Kidwell, Kelley M, Robinson, Adam C, Vangipuram, Kiran, Burness, Monika L, Griggs, Jennifer J, Poznak, Catherine Van, Schott, Anne F, Hayes, Daniel F, Henry, Norah Lynn, Hertz, Daniel L

“…First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration…”
Get full text

Patients carrying by Marcath, Lauren A, Kidwell, Kelley M, Robinson, Adam C, Vangipuram, Kiran, Burness, Monika L, Griggs, Jennifer J, Poznak, Catherine Van, Schott, Anne F, Hayes, Daniel F, Henry, Norah Lynn, Hertz, Daniel L

“…First, evaluate if patients carrying putatively diminished activity genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05…”
Get full text

2043 by Daniel L. Hertz, Kelley M. Kidwell, Kiran Vangipuram, Duxin Sun, N. Lynn Henry

“…OBJECTIVES/SPECIFIC AIMS: Peripheral neuropathy is the dose limiting toxicity of paclitaxel treatment. Paclitaxel pharmacokinetics (PK), specifically the Cmax…”
Get full text

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy by Hertz, Daniel L., Kidwell, Kelley M., Vangipuram, Kiran, Sun, Duxin, Henry, N. Lynn

“…OBJECTIVES/SPECIFIC AIMS: Peripheral neuropathy is the dose limiting toxicity of paclitaxel treatment. Paclitaxel pharmacokinetics (PK), specifically the Cmax…”
Get full text